These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 25944689)

  • 1. Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort.
    Chi KH; Ko HL; Yang KL; Lee CY; Chi MS; Kao SJ
    Oncotarget; 2015 Jun; 6(18):16735-45. PubMed ID: 25944689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.
    Rangwala R; Chang YC; Hu J; Algazy KM; Evans TL; Fecher LA; Schuchter LM; Torigian DA; Panosian JT; Troxel AB; Tan KS; Heitjan DF; DeMichele AM; Vaughn DJ; Redlinger M; Alavi A; Kaiser J; Pontiggia L; Davis LE; O'Dwyer PJ; Amaravadi RK
    Autophagy; 2014 Aug; 10(8):1391-402. PubMed ID: 24991838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double autophagy modulators reduce 2-deoxyglucose uptake in sarcoma patients.
    Chi MS; Lee CY; Huang SC; Yang KL; Ko HL; Chen YK; Chung CH; Liao KW; Chi KH
    Oncotarget; 2015 Oct; 6(30):29808-17. PubMed ID: 26375670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.
    Rangwala R; Leone R; Chang YC; Fecher LA; Schuchter LM; Kramer A; Tan KS; Heitjan DF; Rodgers G; Gallagher M; Piao S; Troxel AB; Evans TL; DeMichele AM; Nathanson KL; O'Dwyer PJ; Kaiser J; Pontiggia L; Davis LE; Amaravadi RK
    Autophagy; 2014 Aug; 10(8):1369-79. PubMed ID: 24991839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.
    Mahalingam D; Mita M; Sarantopoulos J; Wood L; Amaravadi RK; Davis LE; Mita AC; Curiel TJ; Espitia CM; Nawrocki ST; Giles FJ; Carew JS
    Autophagy; 2014 Aug; 10(8):1403-14. PubMed ID: 24991835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
    Saridaki Z; Malamos N; Kourakos P; Polyzos A; Ardavanis A; Androulakis N; Kalbakis K; Vamvakas L; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):35-42. PubMed ID: 21590447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer.
    Patel S; Hurez V; Nawrocki ST; Goros M; Michalek J; Sarantopoulos J; Curiel T; Mahalingam D
    Oncotarget; 2016 Sep; 7(37):59087-59097. PubMed ID: 27463016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of docetaxel and trofosfamide as second-line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC).
    Görn M; Habermann CR; Anige M; Thöm I; Schuch G; Andritzky B; Brandl S; Burkholder I; Edler L; Hossfeld DK; Bokemeyer C; Laack E
    Onkologie; 2008 Apr; 31(4):185-9. PubMed ID: 18418020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
    Katsaounis P; Kotsakis A; Agelaki S; Kontopodis E; Agelidou A; Kentepozidis N; Vamvakas L; Christopoulou A; Karachaliou N; Hatzidaki D; Georgoulias V
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):821-7. PubMed ID: 25702051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors.
    Mehnert JM; Kaveney AD; Malhotra J; Spencer K; Portal D; Goodin S; Tan AR; Aisner J; Moss RA; Lin H; Bertino JR; Gibbon D; Doyle LA; White EP; Stein MN
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):899-907. PubMed ID: 31463691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors.
    Qayed M; Cash T; Tighiouart M; MacDonald TJ; Goldsmith KC; Tanos R; Kean L; Watkins B; Suessmuth Y; Wetmore C; Katzenstein HM
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28134. PubMed ID: 31876107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of refractory metastatic breast cancer with 5-fluorouracil plus levofolinic acid as continuous venous infusion: a phase II study.
    Gebbia V; Borsellino N; Testa A; Tirrito M; Varvara F; Cucchiara A; Mauceri G; Girlando A; Ferrara M; Caruso F
    Anticancer Res; 1999; 19(4C):3553-7. PubMed ID: 10629652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of refractory metastatic breast cancer with 5-fluorouracil and levofolinic acid as 48 hours continuous venous infusion.
    Gebbia V; Mauceri G; Testa A; Tirrito M; Varvara F; Cucchiara A; Borsellino N; Girlando A; Ferrara M; Caruso F
    Anticancer Res; 1999; 19(3B):2289-92. PubMed ID: 10472346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma.
    Fei N; Wen S; Ramanathan R; Hogg ME; Zureikat AH; Lotze MT; Bahary N; Singhi AD; Zeh HJ; Boone BA
    Clin Transl Sci; 2021 Sep; 14(5):1822-1829. PubMed ID: 34002944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer.
    Otsuka H; Fujii T; Toh U; Iwakuma N; Takahashi R; Mishima M; Takenaka M; Kakuma T; Tanaka M; Shirouzu K
    Breast Cancer; 2015 Jul; 22(4):335-42. PubMed ID: 23827973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research progress of hydroxychloroquine and autophagy inhibitors on cancer.
    Shi TT; Yu XX; Yan LJ; Xiao HT
    Cancer Chemother Pharmacol; 2017 Feb; 79(2):287-294. PubMed ID: 27889812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
    Hong YS; Lee J; Lee SC; Hwang IG; Choi SH; Heo JS; Park JO; Park YS; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):321-8. PubMed ID: 17143602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. METRO1: A Phase I Study of Metronomic Chemotherapy in Adults with Advanced Refractory Solid Tumors.
    Launay S; Sabatier R; Brunelle S; Esterni B; Tarpin C; Viret F; Gravis G; Cappiello M; Provansal M; Extra JM; Bertucci F; Viens P; Goncalves A
    Anticancer Res; 2016 Jan; 36(1):293-9. PubMed ID: 26722056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
    Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.